

Resource Summary Report

Generated by [NIF](#) on Sep 7, 2026

NCI-H1781

RRID:CVCL_1494

Type: Cell Line

Proper Citation

RRID:CVCL_1494

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_1494

Proper Citation: RRID:CVCL_1494

Description: Cell line NCI-H1781 is a Cancer cell line with a species of origin Homo sapiens (Human)

Sex: Female

Disease: Minimally invasive lung adenocarcinoma

Defining Citation: [PMID:1311061](#), [PMID:8806092](#), [PMID:11030152](#), [PMID:20215515](#), [PMID:22460905](#), [PMID:22961666](#), [PMID:25485619](#), [PMID:25877200](#), [PMID:26589293](#), [PMID:27397505](#), [PMID:28196595](#), [PMID:29444439](#), [PMID:29681454](#), [PMID:30894373](#), [PMID:31068700](#), [PMID:31803961](#), [PMID:35839778](#)

Comments: Population: Caucasian., Part of: MD Anderson Cell Lines Project., Part of: COSMIC cell lines project., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).

Category: Cancer cell line

Organism: Homo sapiens (Human)

Name: NCI-H1781

Synonyms: H1781, H-1781, NCIH1781

Cross References: CLO:CLO_0008018, EFO:EFO_0006663, ArrayExpress:E-MTAB-2706, ArrayExpress:E-MTAB-2770, ArrayExpress:E-MTAB-3610, ATCC:CRL-5894, BioSample:SAMN03471698, BioSample:SAMN10988321, cancercellines:CVCL_1494, Cell_Model_Passport:SIDM00754, CLS:305731, Cosmic:877432, Cosmic:897517, Cosmic:897728, Cosmic:903568, Cosmic:914946, Cosmic:980985, Cosmic:1032457, Cosmic:1128243, Cosmic:1146888, Cosmic:1802296, Cosmic:1995540, Cosmic-

CLP:1298350, DepMap:ACH-000379, EGA:EGAS00001000610, EGA:EGAS00001000978, GDSC:1298350, GEO:GSM206478, GEO:GSM253348, GEO:GSM274797, GEO:GSM274830, GEO:GSM434280, GEO:GSM794333, GEO:GSM817091, GEO:GSM827359, GEO:GSM887381, GEO:GSM888459, GEO:GSM1374710, GEO:GSM1670191, IARC_TP53:505, IGRhCellID:H1781GEO, LiGeA:CCLE_261, LINCS_LDP:LCL-1643, PharmacDB:NCIH1781_1038_2019, PRIDE:PXD030304, Progenetix:CVCL_1494, Wikidata:Q54907860

ID: CVCL_1494

Record Creation Time: 20220427T220838+0000

Record Last Update: 20260905T181242+0000

Ratings and Alerts

No rating or validation information has been found for NCI-H1781.

No alerts have been found for NCI-H1781.

Data and Source Information

Source: [Cellosaurus](#)

Usage and Citation Metrics

We found 8 mentions in open access literature.

Listed below are recent publications. The full list is available at [NIF](#) .

Siegel F, et al. (2026) Sevabertinib, a Reversible HER2 Inhibitor with Activity in Lung Cancer. Cancer discovery, 16(1), 81.

Ishida M, et al. (2026) AXL-SHC1 signaling axis mediates adaptive resistance to HER2-targeted tyrosine kinase inhibitors in HER2-aberrant lung and gastric cancers. NPJ precision oncology, 10(1).

Nilsson MB, et al. (2026) Loss of Payload Sensitivity and Other Mechanisms of Resistance to T-DXd in HER2-Mutant NSCLC: Implications for Subsequent Responsiveness to HER2 TKIs. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 21(6), 103555.

Pulice JL, et al. (2025) Amplified dosage of the NKX2-1 lineage transcription factor controls its oncogenic role in lung adenocarcinoma. Molecular cell, 85(7), 1311.

Pelos G, et al. (2024) Fast proliferating and slowly migrating non-small cell lung cancer cells are vulnerable to decitabine and retinoic acid combinatorial treatment. International journal of cancer, 154(6), 1029.

McKernan CM, et al. (2022) ABL kinases regulate translation in HER2+ cells through Y-box-binding protein 1 to facilitate colonization of the brain. *Cell reports*, 40(9), 111268.

Koga T, et al. (2021) Activity and mechanism of acquired resistance to tarloxotinib in HER2 mutant lung cancer: an in vitro study. *Translational lung cancer research*, 10(8), 3659.

Sudhan DR, et al. (2020) Hyperactivation of TORC1 Drives Resistance to the Pan-HER Tyrosine Kinase Inhibitor Neratinib in HER2-Mutant Cancers. *Cancer cell*, 37(2), 183.